The HRT Fracture Trap: What A Groundbreaking Lancet Study Just Revealed About Stopping Hormone Therapy

Are you thinking about stopping your menopausal hormone therapy (HRT)? You might want to listen to this first. In this episode, we dive into a groundbreaking new study published in The Lancet Healthy Longevity that tracked nearly 3 million women to uncover what really happens to your bones when you discontinue HRT.

We explore the hidden "fracture trap": how stopping hormone therapy triggers a sudden, sharp spike in fracture risk, often pushing it much higher than the risk levels of women who never used the therapy at all. We will break down how the duration of your treatment impacts your risk rebound, the critical 1-to-10-year post-discontinuation danger zone, and the unexpected long-term silver lining where fracture risk eventually drops back below that of never-users.

Whether you've been on hormone therapy for less than five years or more than a decade, this episode provides essential information you and your doctor need to consider before making any changes to your regimen, including whether you should consider bone health assessments or tapered cessation.

Ready to take control of your hormonal and bone health? Don't traverse the complicated transition of stopping hormone therapy alone. For personalized medical guidance and help, call Dr. Kumar at lifewellmd.com at 561-210-9999.

Disclaimer:
The information provided in this podcast is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before making changes to your supplement regimen or health routine. Individual needs and reactions vary, so it’s important to make informed decisions with the guidance of your physician.

Connect with Us:
If you enjoyed today’s episode, be sure to subscribe, leave us a review, and share it with someone who might benefit. For more insights and updates, visit our website at Lifewellmd.com.

Stay Informed, Stay Healthy: 
Remember, informed choices lead to better health. Until next time, be well and take care of yourself.

Transcript

SPEAKER_00 0:00

Welcome to today's deep dive. I am so excited to get into this one because if you're a woman navigating menopause, you've probably been told that menopausal hormone therapy is just this, you know, very straightforward shield for your bones.

SPEAKER_01 0:13

Right. The classic narrative. You take it, it slows down the bone loss, and your risk of fractures

The Old MHT Bone Story

SPEAKER_01 0:18

goes down. Very simple.

SPEAKER_00 0:19

Exactly. But there's a massive new 2025 study that just came out in the Lancet Healthy Longevity. Yeah. And it completely disrupts that narrative. It reveals this really counterintuitive danger zone.

SPEAKER_01 0:31

Aaron Powell It really does. It's a phenomenal piece of research because it challenges this simplistic assumption the medical community has held on to for a long time.

SPEAKER_00 0:40

Aaron Powell Yeah, the assumption that once you stop hormone therapy, everything just quietly goes back to normal. Like your bone density just sort of gradually returns to baseline. Trevor Burrus, Jr.

SPEAKER_01 0:48

Which, as we're going to see, is absolutely not what happens.

SPEAKER_00 0:51

Aaron Powell Not at all. And you know, before we really unpack this roller coaster of risk, because it is a roller coaster, I think it's important to mention where we're coming from. As part of Dr. Kumar's team at LifeWellMD.com down here in Florida, we see this firsthand. We specialize in health, wellness, and longevity, and this is exactly the kind of science we use every day.

SPEAKER_01 1:10

Oh, absolutely. I mean, we are constantly looking at the long-term structural integrity of the body. And our mission today is to really unpack what happens to your bones decades after you stop taking MHT.

SPEAKER_00 1:23

Aaron Powell Right. We're talking about a timeline that has this surprising initial spike in fragility, which sounds scary, but it's followed by this really unexpected permanent anti-aging payoff.

SPEAKER_01 1:34

Aaron Powell It's wild. But to understand the sheer scale of this roller coaster, we really have to look at why it was a mystery in the first place. I mean, MHT has been prescribed for a very long time.

SPEAKER_00 1:44

Decades, really.

SPEAKER_01 1:45

Yeah, exactly. Yet the landmark research we've always relied on, things like the Women's Health Initiative or the Million Women Study, they had this major inherent blind spot built right into them.

SPEAKER_00 1:54

Aaron Powell Because they just didn't follow the women long enough.

SPEAKER_01 1:56

Aaron Ross Powell Right. They were primarily designed to look at acute risks, you know, cardiovascular events, breast

Why Past Studies Missed Decades

SPEAKER_01 2:03

cancer. So they simply didn't track the participants long enough to capture that really slow, quiet process of skeletal aging.

SPEAKER_00 2:11

Aaron Powell Which makes sense. I mean, those trials usually stop tracking patients like what, five years after they stopped the therapy?

SPEAKER_01 2:16

Aaron Powell About five years, yeah. And a five-year window barely scratches the surface when you're talking about human bone remodeling. It's a decades-long biological marathon.

SPEAKER_00 2:25

Aaron Powell Yeah. If you stop watching after five years, you miss the actual ending of the story. Taking MHT is essentially it's like putting a protective force field around your bones, right?

SPEAKER_01 2:36

That's a great way to look at it.

SPEAKER_00 2:37

And past studies only looked at what happened right as that force field flickered off. But this new study, it's like they set up a 25-year time-lapse camera on the bones to see the permanent architectural changes.

SPEAKER_01 2:50

I love that analogy. And you know, even the older studies that did try to look further down the timeline, they just lacked the statistical power.

SPEAKER_00 2:57

Because they didn't have enough people.

SPEAKER_01 2:58

Exactly. They didn't have enough women enrolled to segment the data by different types of hormones or, you know, different durations of use.

SPEAKER_00 3:05

Which brings us to how this 2025 study finally cracked the code. The researchers utilized the UK's clinical practice research data link, the CPRD. And this isn't just some small clinical trial with a few thousand volunteers.

SPEAKER_01 3:20

No, this is massive. The CPRD captures primary care and hospital data for millions of people. It is literally that 25-year

The 2025 Lancet Data Set

SPEAKER_01 3:28

time-lapse camera you mentioned.

SPEAKER_00 3:29

What were the actual numbers they were looking at?

SPEAKER_01 3:31

Well, they had access to over 648,000 women who had experienced a fracture. Wow. Yeah. And then they matched those cases against 2.3 million women who had not experienced a fracture.

SPEAKER_00 3:41

Aaron Powell Okay, wait. Matching 648,000 against 2.3 million, that's how you completely eliminate the statistical noise, isn't it?

SPEAKER_01 3:49

Aaron Powell Precisely. You can control for all those little variables that might skew a smaller study. They match them by age, by their specific medical practice. So they implicitly control for all these regional and socioeconomic lifestyle factors.

SPEAKER_00 4:00

Aaron Powell It's a true apples to apples comparison. And the age demographic is super important here, too. The average age of a fracture case in this data was 68.5 years old.

SPEAKER_01 4:11

Yes, and over a quarter of the patients were older than 80.

SPEAKER_00 4:14

Right. So we're not just looking at women who are fresh out of menopause, we are looking at women well into their postmenopausal years. It's a true picture of long-term aging.

SPEAKER_01 4:22

Aaron Powell, which is exactly what we focus on at Life WellMD. And this brings us to the actual footage from that time-lapse camera. The researchers broke the post-MHT journey into three very distinct phases.

SPEAKER_00 4:35

Okay, let's break these phases down. What's phase one?

SPEAKER_01 4:37

Phase one is current use. So women actively taking the therapy or who stopped within the last 12 months.

SPEAKER_00 4:44

Aaron Powell And this aligns with what we already knew, right? The protection is high. The study

Three Phases Of Fracture Risk

SPEAKER_00 4:48

found like a 25% drop in fracture risk compared to women who never used MHT.

SPEAKER_01 4:53

Exactly. The medication does exactly what it's supposed to do while it's in your system. But phase two, this is where the narrative completely fractures.

SPEAKER_00 5:00

No pun intended.

SPEAKER_01 5:01

Right. Phase two is the window between one and ten years post-discontinuation. When a woman stops the therapy, her fracture risk does not just smoothly go back to normal. It spikes sharply.

SPEAKER_00 5:12

Wait, really? It spikes?

SPEAKER_01 5:14

Yes. It routinely exceeds the risk levels of comparable women who never took MHT in the first place.

SPEAKER_00 5:20

Okay, left pause and really look at that because it is so counterintuitive. If you are listening to this, you're probably thinking, why does removing a protective medication cause a biological crisis?

SPEAKER_01 5:31

It's all about the cellular mechanics. Taking MHT puts your bone dismantling cells into a state of forced hibernation.

SPEAKER_00 5:37

Right. So when you stop, you're not just going back to normal. You are waking all those cells up at the exact same time.

SPEAKER_01 5:43

Exactly. The mechanism is called a rebound effect. Bone is living tissue constantly being broken down by cells called osteoclasts and rebuilt by osteoblasts.

SPEAKER_00 5:52

Osteoclasts break it down, osteoblasts build it up.

SPEAKER_01 5:55

You got it. And estrogen naturally suppresses those osteoclasts, it limits their activity. So when you introduce systemic estrogen through MHT, you are heavily sedating that demolition crew.

SPEAKER_00 6:05

Which gives the builder cells, the osteoblasts, a chance to maintain or even increase the bone density.

SPEAKER_01 6:11

Right. But when you abruptly stop the MHT, that synthetic estrogen clears out very quickly. And the sudden absence of suppression triggers the osteoclast to go into hyperdrive.

SPEAKER_00 6:22

So you have this massive surge of hungry, bone-eating cells waking up all at once.

SPEAKER_01 6:27

Yes. And the builder cells just can't keep up? The result is this really rapid, steep loss of bone mineral density that temporarily pushes your structural fragility way above someone who never artificially suppressed their system.

SPEAKER_00 6:40

Aaron Powell To ground this in the study's numbers, they estimated an extra 14 fractures per 10,000 women years during this specific one to 10 year window, right? For short-term users.

SPEAKER_01 6:50

Yes. And translating women years is important, so it doesn't just sound like abstract math. If you observe 10,000 women for one year, that's 10,000 women years.

SPEAKER_00 6:57

So to put that into perspective for you listening, if a baseline group of 10,000 postmenopausal women who never took MHT experiences, let's say 150 fractures, the group that recently stopped MHT is experiencing 164 fractures.

SPEAKER_01 7:11

Exactly. And in a primary care setting, that is a visually noticeable, very statistically significant surge in broken bones.

SPEAKER_00 7:18

It's a huge surge. But and here's where it gets crazy this scary spike in phase two is followed by phase three.

SPEAKER_01 7:26

Which is arguably the most critical finding in the whole study. Phase three looks at the risk more than 10 years after stopping.

SPEAKER_00 7:33

Right. This is where the dust finally settles from that cellular demolition derby we just talked about.

SPEAKER_01 7:37

And when the dust settles, the risk drops again, the trajectory smooths out, and your fraction risk actually falls below the levels of the never users.

SPEAKER_00 7:46

Wait, it falls below.

SPEAKER_01 7:47

Below. For women who were long-term users of estrogen-only therapy, looking at them more than a decade out, there were 20 fewer fractures per 10,000 women years compared to women who never took it.

SPEAKER_00 7:59

Wow. The researchers call this a persistent long-term attenuation of age-related bone decline. Basically, the therapy fundamentally altered the biological aging of the skeleton.

SPEAKER_01 8:09

Yes. Your bones age slower for the rest of your life, even though the medication has been out of your bloodstream for decades.

SPEAKER_00 8:15

That is incredible. It really forces a re-evaluation of how we view temporary interventions. Like we usually think a pill only works while you swallow it.

SPEAKER_01 8:23

Right. Active window only. But this proves the structural legacy of MHT outlasts the active pharmacological presence by decades.

SPEAKER_00 8:32

Okay, so understanding that this timeline is basically a volatile roller coaster, it brings up the next obvious question for anyone making these healthcare choices. Can you control the ride? Because a 10-year danger zone of elevated fracture risk, I mean, that's a long time to walk around hoping you don't slip on a wet floor.

SPEAKER_01 8:49

It's terrifying. But the data gives us a clear answer on how to predict that rebound spike. Your experience on the roller coaster depends almost entirely on the duration of the therapy.

SPEAKER_00 8:58

The duration trade-off.

SPEAKER_01 8:59

Exactly. The study compares short-term use, which is taking it for less than five years, against long-term use, which is five or more years.

SPEAKER_00 9:07

Let's start with short-term. How does that look?

SPEAKER_01 9:09

So short-term use

The Rebound Effect Explained

SPEAKER_01 9:10

gives you more modest protection while you're actively on it. Because you didn't suppress bone turnover for very long, the rebound spike in that one to ten year window is much smaller.

SPEAKER_00 9:19

It's a smoother transition back to normal. But the trade-off is that the long-term payoff is minimal. Right. Right?

SPEAKER_01 9:25

You only see a very slight reduction in fractures when you hit your 70s and 80s.

SPEAKER_00 9:29

Okay, but long-term use is the exact opposite profile. For women taking it for five, 10, 15 years, the initial protection is massive. Like 48 fewer fractures per 10,000 women years while active.

SPEAKER_01 9:43

It is incredibly effective at halting burn degradation. But, and this is a big but the longer you suppress that system, the harder it snaps back when you remove the suppression.

SPEAKER_00 9:52

So when a long-term user stops, it triggers a severe, extreme spike in fracture risk immediately after. Yes.

SPEAKER_01 9:59

The bone turnover goes into absolute hyperdrive because the body became heavily reliant on that external hormone.

SPEAKER_00 10:06

But if they can just navigate that volatile 10-year window without breaking a hip, they arrive at the ultimate payoff. More than 10 years out, those former long-term users have the absolute lowest fracture risk in old age.

SPEAKER_01 10:17

The permanent attenuation is at its strongest.

SPEAKER_00 10:19

It sounds exactly like a financial investment strategy. You know, short-term use is like a low-yield savings account. It's safe, modest returns, almost no penalty if you withdraw.

SPEAKER_01 10:28

That's a great analogy.

SPEAKER_00 10:30

And long-term use is a volatile high-yield stock, huge compounding returns while invested, a terrifying drop if you pull your funds out suddenly during a correction. But if you weather the storm, you come out significantly ahead in retirement.

SPEAKER_01 10:44

I love that. Taking that into clinical practice, the duration trade-off is the most actionable finding here. It definitively maps out the risk-reward ratio.

SPEAKER_00 10:53

Aaron Powell But I gotta play devil's advocate for a second. If long-term use gives you 48 fewer fractures while you're on it, but guarantees a severe crash when you stop, does the math actually work out in your favor?

SPEAKER_01 11:04

Mathematically, yes. The net benefit is positive. The overall cumulative incidence of fractures is lower for long-term users across their whole lifespan. But exactly. The issue is that a single severe fragility fracture, like breaking a hip in that rebound phase, can cause a catastrophic decline in quality of life.

SPEAKER_00 11:22

Yeah, a mathematically positive net benefit over 25 years doesn't really matter if you suffer a devastating injury in year three of the rebound.

SPEAKER_01 11:30

Exactly. Which brings us to the crucial so what of this whole analysis. We've mapped out the data, the cellular mechanics, but for you listening, what do you actually do with this?

SPEAKER_00 11:40

Right. If you or someone you love is planning to stop MHT, are you just doomed to enter this danger zone without a parachute?

SPEAKER_01 11:48

Absolutely not. And the study makes a very explicit pivot here from just observing data to making clinical recommendations. They note that this MHT rebound effect is strikingly similar to what happens when patients stop taking denosumab.

SPEAKER_00 12:01

Oh, right.

SPEAKER_01 12:11

It's highly effective. But doctors already know that when a patient stops taking denosumab, there is a rapid aggressive increase in bone resorption. The osteoclasts surge back.

SPEAKER_00 12:20

Aaron Ross Powell Leading to profound bone loss and a super high risk of multiple vertebral fractures. It's a known clinical crisis.

SPEAKER_01 12:27

Exactly. Doctors know you cannot just pull a patient off denosumab cold turkey. You have to anticipate and manage that breakdown.

SPEAKER_00 12:35

And this new Lancet data is basically waving a

Long Use Versus Short Use

SPEAKER_00 12:38

giant red flag saying, hey, we need to treat MHT discontinuation with that exact same level of strategic caution.

SPEAKER_01 12:45

Yes. The transition has to be actively managed. It cannot just be treated as a casual change in your daily routine. Going cold turkey is the specific trigger for those severe spikes.

SPEAKER_00 12:56

The sudden drop in systemic estrogen is what shocks the cells. This is honestly where our work at Life Well MD really intersects with the data.

SPEAKER_01 13:03

Oh, absolutely.

SPEAKER_00 13:04

Because Dr. Kumar has been helping selected postmenopausal women with bioidentical hormone replacement therapy, BHRT, for over five years. And the core of that practice is that it is medically supervised and monitored for maximum effectiveness with minimal risk.

SPEAKER_01 13:19

Which is exactly what the study is calling for. The researchers suggest prioritizing tapered cessation, slowly, methodically weaning the patient off the hormones over an extended period.

SPEAKER_00 13:29

You don't just drop off a cliff, you need a ramp.

SPEAKER_01 13:31

Yeah.

SPEAKER_00 13:32

Especially for women who already have known risk factors, right? Like a family history of osteoporosis, a lower BMI, or if they smoke.

SPEAKER_01 13:40

Or if they were on combined therapy for a very long time. Dropping them off the cliff without a parachute is unnecessarily risky.

SPEAKER_00 13:46

So what does managing that gap actually look like?

SPEAKER_01 13:49

It might require proactive bone assessments, regular the XA scans to monitor the actual density during the transition.

SPEAKER_00 13:56

And maybe transitional non-hormonal meds like bisphosphonates.

SPEAKER_01 14:00

Exactly, using bisphosphonates to bridge the gap, just to suppress the bone turnover enough to prevent a fracture while the body adjusts to having less estrogen.

SPEAKER_00 14:09

It's all about ensuring you get the maximum benefit from your years on the therapy while minimizing the risk when you transition off. And if you're listening and thinking, hey, I need a supervised plan for this, that is exactly what we do. You can reach out to us at LifeWellMD, just call 561-210-9999 to start your wellness journey today. Dr. Kumar's supervised approach is literally designed to safely cross that shaky bridge we've been talking about.

SPEAKER_01 14:33

Because proactive, closely monitored care is really the only way to safely ride this biological roller coaster. And when you step back and look at the totality of this 25-year data set, the ultimate takeaway is profoundly optimistic.

SPEAKER_00 14:47

It really is. I mean, to summarize what we've unpacked today, we used to think menopausal hormone therapy was just a temporary band-aid, right? You use it for hot flashes, nice sweats, get some bone protection, and when you stop, you just go back to square one.

SPEAKER_01 14:59

Aaron Powell But this massive data set proves that narrative is fundamentally false. MHT permanently alters the biological aging trajectory of your bones.

SPEAKER_00 15:08

Even though the road off the therapy has this volatile, medically significant speed bump, the final destination is a stronger, more resilient skeleton in your 70s, 80s, and beyond.

SPEAKER_01 15:20

It completely rewrites our understanding of long-term pharmacology, how an intervention in midlife cascades through our later decades.

SPEAKER_00 15:27

It's mind-blowing. Which leaves us with a rather profound final thought for you to consider today. And this extends way beyond the scope of just bone density.

SPEAKER_01 15:35

Yeah, think about this. If taking a hormone therapy for just a few years in your 50s can permanently rewire the biological aging process of your skeleton, altering cellular behavior decades after that medication has completely cleared your system.

SPEAKER_00 15:50

Right. What other hidden biological clocks in the human body might be permanently paused or irrevocably altered by our short-term medical interventions?

SPEAKER_01 15:59

It's a massive question.

SPEAKER_00 16:00

It really makes you realize that every significant medical choice we make

Managing The Danger Zone

SPEAKER_00 16:05

is like dropping a heavy stone into a pond, and we are still measuring the ripples 30 years later. The initial medication might clear your bloodstream, but the architecture of your body remembers it was there.

SPEAKER_01 16:16

Beautifully said.